Laurus Labs Ltd. Corporate Filings & Announcements

Latest corporate announcements and filings from Laurus Labs Ltd. on BSE

Load latest

Laurus Labs Ltd.

09 Oct 2018

603.45

1.38%

Company Update

Certificate Under Regulation 40(9) Of SEBI (LODR) Regulations 2015

BSE India

Laurus Labs hereby attach the Certificate under Regulation 40(9) of SEBI (LODR) Regulations 2015 for the half year ended September 30, 2018. The same is being sent herewith for your information and records.

pdf

Laurus Labs Ltd.

09 Oct 2018

603.45

1.38%

Company Update

Statement Of Investor Complaints For The Quarter Ended September 2018

BSE India

No.of Investor complaints pending at the beginning of the quarter No.of Investor complaints received during the quarter No.of Investor complaints disposed of during the quarter No.of Investor complaints unresolved at the end of the quarter 0220 Name of the Signatory :- G. VENKATESWAR REDDYDesignation :- Company Secretary and Compliance Officer

Laurus Labs Ltd.

20 Sep 2018

603.45

1.38%

Corp. Note

Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPS

BSE India

Allotment of Equity Shares on exercise of ESOPs on 20th September 2018.

pdf

Laurus Labs Ltd.

29 Aug 2018

603.45

1.38%

Company Update

Announcement under Regulation 30 (LODR)-Press Release / Media Release

BSE India

Press Release Laurus Labs receives USFDA approval for Metformin Hydrochloride Tablets USP Hyderabad, August 29, 2018, Laurus Labs Ltd. (Laurus BSE: 540222, NSE: Lauruslabs, ISIN: INE947Q01010) Laurus Labs is pleased to announce that the Company has received an approval from United States Food and Drug Administration (US FDA) for Metformin Hydrochloride Tablets USP 500mg, 850mg and 1000mg which are used for treatment of diabetes....

pdf

Laurus Labs Ltd.

16 Aug 2018

603.45

1.38%

SAST

Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations, 2011

BSE India

The Exchange has received the disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Naga Rani Chava

pdf

Laurus Labs Ltd.

14 Aug 2018

603.45

1.38%

Earnings Call

Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome

BSE India

Please refer our intimation letter dated July 31, 2018 wherein we have intimated the schedule of Investor/Analyst call on August 4, 2018. In this connection please find attached Transcript of Conference Call.

pdf

Laurus Labs Ltd.

03 Aug 2018

603.45

1.38%

Investor Presentation

Corrigendum To Investor Presentation Dated August 3, 2018-Laurus Labs Limited

BSE India

Please find attached Corrigendum to Investor Presentation dated August 3, 2018-Laurus Labs Limited

pdf

Laurus Labs Ltd.

03 Aug 2018

603.45

1.38%

Investor Presentation

Investor /Analysts Presentation

BSE India

Please refer to our letter dated 31st July, 2018, wherein we have intimated the schedule of Investors/Analysts call on 4th August, 2018. In this connection, we enclose herewith the presentation to the Investors/Analysts on the Unaudited Financial Results of the Company for the Quarter ended June 30, 2018.

pdf

Laurus Labs Ltd.

03 Aug 2018

603.45

1.38%

Result

Press Release

BSE India

Please find herewith the Press Release of the Results of the Quarter ended June 30, 2018.

pdf

Laurus Labs Ltd.

03 Aug 2018

603.45

1.38%

Corp. Note

Outcome of Board Meeting

BSE India

Pursuant to Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed herewith the Unaudited Financial Results of the Company for the Quarter ended June 30, 2018 as approved by the Board of Directors of the Company in their Meeting held on August 3, 2018 along with the Limited Review Report issued by the Statutory Auditors of the Company.

pdf

Is Laurus Labs Ltd. worth buying?

1218 Votes:

Buy 79.56%

Sell 10.84%

Hold 9.61%

RESEARCH REPORTS

Accumulate SEE REPORTS >

pdf

Hold SEE REPORTS >

pdf